Brief: Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat

Calithera Biosciences

02/07/2019 13:58

July 2 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES INITIATES PHASE 1/2 TRIAL OF
TELAGLENASTAT
IN COMBINATION WITH PFIZER’S CDK4/6 INHIBITOR PALBOCICLIB
    * CALITHERA BIOSCIENCES - ANNOUNCED TREATMENT OF FIRST
PATIENT IN
PHASE 1/2 TRIAL OF GLUTAMINASE INHIBITOR TELAGLENASTAT WITH
PFIZER'S IBRANCE
    * CALITHERA BIOSCIENCES INC - AS PART OF AGREEMENT, PFIZER
IS
PROVIDING PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL
SUPPORT

Source text for Eikon:  ID:nGNX8fCkJq 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))